Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.71 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.71 |
| ▸ | POLB | P06746 | 2/20 | 0.56 |
| ▸ | LMNA | P02545 | 5/20 | 0.55 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.55 |
| ▸ | MEN1 | O00255 | 1/20 | 0.55 |
| ▸ | MAPT | P10636 | 2/20 | 0.46 |
| ▸ | IDO1 | P14902 | 2/20 | 0.46 |
| ▸ | TDO2 | P48775 | 2/20 | 0.46 |
| ▸ | IDO2 | Q6ZQW0 | 2/20 | 0.46 |
| ▸ | NPC1 | O15118 | 1/20 | 0.46 |
| ▸ | NTRK1 | P04629 | 1/20 | 0.46 |
| ▸ | ALOX5 | P09917 | 1/20 | 0.46 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.46 |
| ▸ | HTT | P42858 | 1/20 | 0.46 |
| ▸ | MAPK8 | P45983 | 1/20 | 0.46 |
| ▸ | RAB9A | P51151 | 1/20 | 0.46 |
| ▸ | NTRK2 | Q16620 | 1/20 | 0.46 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.46 |
| ▸ | HCAR1 | Q9BXC0 | 3/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9338110 | 0.83 | L3MBTL1 (1.00) | ALDH1A1L3MBTL1POLBLMNAKMT2A | |
| SCHEMBL24090149 | 0.80 | ALDH1A1 (0.67) | ALDH1A1L3MBTL1POLBLMNAKMT2A | |
| SCHEMBL9670692 | 0.80 | LMNA (0.58) | ALDH1A1L3MBTL1POLBLMNAKMT2A | |
| SCHEMBL5028796 | 0.78 | LMNA (0.57) | ALDH1A1L3MBTL1POLBLMNAKMT2A | |
| SCHEMBL5028779 | 0.78 | ALDH1A1 (0.73) | ALDH1A1L3MBTL1LMNAKMT2AMEN1 | |
| SCHEMBL1129120 | 0.77 | ALDH1A1 (0.54) | ALDH1A1L3MBTL1POLBLMNAKMT2A | |
| SCHEMBL9670555 | 0.76 | NPC1 (0.58) | ALDH1A1L3MBTL1POLBLMNAKMT2A | |
| SCHEMBL1129431 | 0.75 | ALDH1A1 (0.49) | ALDH1A1L3MBTL1POLBLMNAKMT2A | |
| SCHEMBL1129535 | 0.75 | ALDH1A1 (0.49) | ALDH1A1L3MBTL1POLBLMNAKMT2A | |
| SCHEMBL1129588 | 0.75 | L3MBTL1 (0.68) | ALDH1A1L3MBTL1LMNAKMT2AMEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 21 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8450333-B2 | Molecules for regulating cell death | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2013-05-28 | — | — | US | claimed |
| WO-2005051974-A2 | NOVEL MOLECULES FOR REGULATING CELL DEATH | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2005-06-09 | — | — | WO | claimed |
| US-20050038051-A1 | Novel molecules for regulating cell death | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2005-02-17 | — | — | US | claimed |
| US-11351168-B1 | 2,4-disubstituted pyrimidines useful as kinase inhibitors | CELGENE CAR LLC (BM) | 2022-06-07 | — | — | US | disclosed |
| US-10828300-B2 | Substituted 2,4-diaminopyrimidines as kinase inhibitors | CELGENE CAR LLC (BM) | 2020-11-10 | — | — | US | disclosed |
| US-10596172-B2 | 2,4-disubstituted pyrimidines useful as kinase inhibitors | CELGENE CAR LLC (BM) | 2020-03-24 | — | — | US | disclosed |
| EP-3549934-A1 | HETEROARYL COMPOUNDS AND USES THEREOF | Celgene CAR LLC (BM) | 2019-10-09 | — | — | EP | disclosed |
| US-20190192512-A1 | HETEROARYL COMPOUNDS AND USES THEREOF | BRISTOL-MYERS SQUIBB COMPANY | 2019-06-27 | — | — | US | disclosed |
| US-20190117650-A1 | HETEROARYL COMPOUNDS AND USES THEREOF | BRISTOL-MYERS SQUIBB COMPANY | 2019-04-25 | — | — | US | disclosed |
| EP-2361248-B1 | HETEROARYL COMPOUNDS AND USES THEREOF | CELGENE CAR LLC (BM) | 2018-09-19 | — | — | EP | disclosed |
| US-10010548-B2 | 2,4-disubstituted pyrimidines useful as kinase inhibitors | CELGENE CAR LLC (BM) | 2018-07-03 | — | — | US | disclosed |
| US-20170100397-A1 | HETEROARYL COMPOUNDS AND USES THEREOF | BRISTOL-MYERS SQUIBB COMPANY | 2017-04-13 | — | — | US | disclosed |
| US-20160303121-A1 | HETEROARYL COMPOUNDS AND USES THEREOF | BRISTOL-MYERS SQUIBB COMPANY | 2016-10-20 | — | — | US | disclosed |
| US-8609679-B2 | 2,4-diaminopyrimidines useful as kinase inhibitors | CELGENE AVILOMICS RESEARCH, INC. (US) | 2013-12-17 | — | — | US | disclosed |
| US-20130165462-A1 | HETEROARYL COMPOUNDS AND USES THEREOF | CELGENE AVILOMICS RESEARCH, INC. (US) | 2013-06-27 | — | — | US | disclosed |
| US-8450335-B2 | 2,4-disubstituted pyrimidines useful as kinase inhibitors | CELGENE AVILOMICS RESEARCH, INC. (US) | 2013-05-28 | — | — | US | disclosed |
| US-8450333-B2 | Molecules for regulating cell death | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2013-05-28 | — | — | US | disclosed |
| US-20080287473-A1 | NOVEL MOLECULES FOR REGULATING CELL DEATH | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2008-11-20 | — | — | US | disclosed |
| WO-2005051974-A2 | NOVEL MOLECULES FOR REGULATING CELL DEATH | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2005-06-09 | — | — | WO | disclosed |
| US-20050038051-A1 | Novel molecules for regulating cell death | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2005-02-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (11 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160303121-A1 | HETEROARYL COMPOUNDS AND USES THEREOF | ABCG2, CYP3A43, CYP3A5 | ALDH1A1 684/4885L3MBTL1 3899/4885POLB 3726/4885 |
| US-20080287473-A1 | NOVEL MOLECULES FOR REGULATING CELL DEATH | AIFM1, BAX, HSPE1 | ALDH1A1 4015/4885L3MBTL1 421/4885POLB 3457/4885 |
| US-11351168-B1 | 2,4-disubstituted pyrimidines useful as kinase inhibitors | DCK, CDK2, DTYMK | ALDH1A1 2583/4885L3MBTL1 2337/4885POLB 1191/4885 |
| US-20190192512-A1 | HETEROARYL COMPOUNDS AND USES THEREOF | ABCG2, CYP3A43, CYP3A5 | ALDH1A1 684/4885L3MBTL1 3899/4885POLB 3726/4885 |
| US-10010548-B2 | 2,4-disubstituted pyrimidines useful as kinase inhibitors | DCK, CDK2, DTYMK | ALDH1A1 2583/4885L3MBTL1 2337/4885POLB 1191/4885 |
| US-10828300-B2 | Substituted 2,4-diaminopyrimidines as kinase inhibitors | ABL1, DCK, ERBB2 | ALDH1A1 1989/4885L3MBTL1 2144/4885POLB 1267/4885 |
| US-20190117650-A1 | HETEROARYL COMPOUNDS AND USES THEREOF | ABCG2, CYP3A43, CYP3A5 | ALDH1A1 684/4885L3MBTL1 3899/4885POLB 3726/4885 |
| US-20130165462-A1 | HETEROARYL COMPOUNDS AND USES THEREOF | ABCG2, CYP3A43, CYP3A5 | ALDH1A1 684/4885L3MBTL1 3899/4885POLB 3726/4885 |
| US-20050038051-A1 | Novel molecules for regulating cell death | AIFM1, BAX, HSPE1 | ALDH1A1 4015/4885L3MBTL1 421/4885POLB 3457/4885 |
| US-10596172-B2 | 2,4-disubstituted pyrimidines useful as kinase inhibitors | DCK, CDK2, DTYMK | ALDH1A1 2583/4885L3MBTL1 2337/4885POLB 1191/4885 |
| US-20170100397-A1 | HETEROARYL COMPOUNDS AND USES THEREOF | ABCG2, CYP3A43, CYP3A5 | ALDH1A1 684/4885L3MBTL1 3899/4885POLB 3726/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.